Agrylin (anagrelide hydrochloride) capsules is indicated for treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events Agrylin (anagrelide hydrochloride) capsules Initial U.S. Approval: 1997. Agrylin (anagrelide hydrochloride) capsules should be administered under the supervision of a qualified physician experienced in the uses of cancer chemotherapeutic agents.

Where can I buy Agrylin capsules?

Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow and Pune and other cities in India. with over 20 years of domain experience.

The order for Agrylin (anagrelide hydrochloride) Tablets will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

For Agrylin or anagrelide hydrochloride Tablets price in India. Please call at M: +91 9811747774 or Email Us to know more details about the medicine and its cost price in India.
Agrylin (anagrelide hydrochloride) capsules

Get In Touch

Facilitator under Patient Assistance Programs In India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Agrylin (anagrelide hydrochloride) on prescription and Import License in Patient's Name only.

For overseas patients, Agrylin (anagrelide hydrochloride) Tablets can be made available in Send your enquiry to find Agrylin (anagrelide hydrochloride) Tablets in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

FDA News Release

Platelet-Reducing Agent Available Again.
Dated: December 05, 2016

ReadMore